Have any questions? 706-721-6582 or cts@augusta.edu
The purpose of this study is to test study treatments that combine an investigational drug (tucatinib, which is also known as ONT-380) with two approved drugs (capecitabine and trastuzumab) in patients with advanced breast cancer to find out what effects, good or bad, it may have.